Document:

EXHIBIT 10.15                                                  [GRAPHIC OMITTED]

October 20, 2006

John H. Shaw III
President & Co-Chairman
Legend Merchant Group, Inc.
30 Broad Street, 38th Floor
New York, NY 10004

RE:   Private Placement of Securities for QuantRx Biomedical Corporation

This binding letter of intent confirms our understanding that QuantRx Biomedical
Corporation (or the company) has engaged Legend Merchant Group, Inc., a licensed
broker/dealer, to act as a "non-exclusive" selling dealer of the Company
("Selling Dealer") in connection with a best efforts private placement offering
of the Company's Common Stock and Warrants (the "Placement"). This letter will
confirm our acceptance and set Forth the terms of the engagement agreed to
between Legend Merchant Group and the Company.

      1.   Information. In connection with the Selling Dealer's activities
hereunder, the Company will furnish Legend Merchant Group with all material and
information regarding the business and financial condition of the Company,
including but not limited to last three years financial statements, financial
projections, material contracts, all documents evidencing indebtedness, sales
and marketing plans, labor and executive compensation agreements, environmental
matters, tax matters, intellectual property matters, litigation matters and such
other data, information or files that may be material to the business of the
Company or otherwise requested by Legend Merchant Group (the "Information"). The
Company will cooperate with Legend Merchant Group in furnishing all information
as may be requested by Legend Merchant Group from time to time and will provide
access to the officers, directors, employees, accountants, counsel and other
professionals of the Company to the extent Legend Merchant Group deems
appropriate. The Company represents and warrants that all Information, including
but not limited to the Company's financial statements, will be complete and
correct in all material respects and will not contain any untrue statement of a
material fact or omit to

                         QUANTRX BIOMEDICAL CORPORATION
      100 SOUTH MAIN STREET / SUITE 300 - DOYLESTOWN / PENNSYLVANIA - 18901
                      TEL: 267-880-1595 / FAX: 267-880-1596

<PAGE>

state a material fact necessary in order to make the statements therein not
misleading. The Company recognizes and confirms that the non-exclusive Selling
Dealer: (i) will use and rely primarily on the Information and on information
available from generally recognized public sources in performing the services
contemplated by this letter without having independently verified the same; (ii)
is authorized as the Company's financial advisor and selling dealer to transmit
to any prospective investor a copy or copies, forms of purchase agreements and
any other legal documentation supplied to the Selling Dealer for transmission to
any prospective investor by or on behalf of the Company or by any of the
Company's officers, representatives or agents, in connection with the
performance of the Selling Dealer's services hereunder or any transaction
contemplated hereby; (iii) does nor assume responsibility for the accuracy or
completeness of the Information and such other information; (iv) will not make
an appraisal of any assets of the Company; and (v) retains the right to continue
to perform due diligence during the course of the engagement. Accordingly, the
Company agrees that Legend Merchant Group assumes no responsibility for the
accuracy and completeness of the Information. The Selling Dealer agrees to keep
the Information confidential and will not make use thereof, except in connection
with services hereunder for the Company, unless; (i) disclosure is required by
law or requested by any government, regulatory or self-regulatory agency or body
in which event the Selling Dealer will provide the Company with reasonable
advance notice of such proposed disclosure; (ii) any Information is or becomes
generally available to the public; or (iii) any Information was or becomes
available to the Selling Dealer on a non-confidential basis from a source other
than the Company or any of its representatives.

      2.   Compensation. As compensation for services rendered and to be
rendered hereunder by Legend Merchant Group, the Company agrees to pay Legend
Merchant Group as follows:

                  a) An amount in cash equal to eight percent (8%) of the
principal amount of any Placement placed and/or committed by any investor
originating from a relationship with the Company and payable at the time of each
closing of the Financing ("Placement Fee").

                  b) The Company will issue to Legend Merchant Group warrants to
purchase shares of the Company's Common Stock equal to ten percent (10%) of the
number of common shares ("Shares") issued in the Placement. Such Warrants will
be issued pursuant to a Warrant Agreement to be signed by the Company and Legend
Merchant Group or any assignee of Legend Merchant Group, which agreement shall
provide, among other things, that the Warrants shall be exercisable at an
exercise price equal to the price at which the Shares are sold to investors in
the Placement, shall expire seven (7) years from the date of first closing,
include registration rights at the time that all shares issued in his Placement
are registered, and such other terms as are normal and customary for Warrants of
this type.

                         QUANTRX BIOMEDICAL CORPORATION
      100 SOUTH MAIN STREET / SUITE 300 - DOYLESTOWN / PENNSYLVANIA - 18901
                      TEL: 267-880-1595 / FAX: 267-880-1596

<PAGE>

                  c) Notwithstanding any termination of this Agreement pursuant
to the terms hereof or otherwise, if on or before the twelve (12) month
anniversary of the final closing of the Placement, the Company enters into a
definitive commitment relating to a Placement (or any portion thereof), capital
raise, or consummates a Placement with any party, or the Company enters into a
definitive commitment relating to a Placement (or any portion thereof) with any
financing source introduced to the Company by Legend Merchant Group, the Company
agrees to pay Legend Merchant Group all such compensation pursuant to the rams
of Section 2 "Compensation" of this Agreement.

      3.   Certain Placement Procedures. The Company and the Selling Dealer
each represents to the other that it has not taken, and the Company and the
Selling Dealer each agrees with the other that it will not take any action,
directly or indirectly, so as to cause the Placement to fail to be entitled to
rely upon the exemption from registration afforded by Section 4(2) of the
Securities Act of 1933, as amended (the "Act). In effecting the Placement, the
Company and the Selling Dealer each agrees to comply in all material respects
with applicable provisions of the Act and any regulations thereunder and any
applicable state laws and requirements. The Company agrees that any
representations and warranties made by it to any investor in the Placement shall
be deemed also to be made to the Selling Dealer for its benefit. The Company
agrees that it shall cause any opinion of its counsel delivered to any investors
in the Placement also to be addressed and delivered to the Selling Dealer, or so
cause such counsel to deliver to the Selling Dealer a letter authorizing it to
rely upon such opinion. Upon completion of the Placement, all shares placed by
the Selling Dealer will be deposited into a Legend Merchant Group client account
for the benefit of each investor.

      4.   Termination. Survival Of Provisions. This Agreement may be
terminated by the Selling Dealer or the Company at any time upon ten (10) days
prior written notice to the other party, provided, however, that (a) any
termination or completion of Legend Merchant Group's engagement hereunder shall
not affect the Company's obligation to indemnify Legend Merchant Group as
provided in the separate letter agreement referred to above and (b) any
termination by the Company of Legend Merchant Group's engagement hereunder shall
not affect the Company's obligation to pay fees to the extent provided for in
Section 2(c) herein, and any unpaid amounts thereunder shall be accelerated and
be immediately due and payable to Legend Merchant Group on the termination date;
and (c) any termination by Legend Merchant Group of Legend Merchant Group's
engagement hereunder shall not affect the Company's obligation to pay fees and
reimburse the expenses accruing prior to such termination to the extent provided
for herein. All such fees and reimbursements due the Selling Dealer, shall be
paid to the Selling Dealer on or before the Termination Date (in the event such
fees and reimbursements are earned or owed as of the Termination Date) or upon
the closing of the Placement or any applicable portion thereof (in the event
such fees are due pursuant to the terms of Section 2 "Compensation" hereof).

                         QUANTRX BIOMEDICAL CORPORATION
      100 SOUTH MAIN STREET / SUITE 300 - DOYLESTOWN / PENNSYLVANIA - 18901
                      TEL: 267-880-1595 / FAX: 267-880-1596

<PAGE>

      5.   Governing Law; Amendment; Headings. This Agreement and all
controversies arising from and relating to performance under this agreement
shall be governed by and construed in accordance with the laws of the State of
New York, without giving effect to such state's rules concerning conflicts of
laws. This Agreement may not be modified or amended except in writing duly
executed by the parties hereto. The section headings in this Agreement have been
inserted as a matter of Convenience of reference and are not part of this
Agreement

      6.   Nondisclosure Of Confidential Information. Legend Merchant Group and
the Company mutually agree that they will not disclose any confidential
information received from the other party to others except with the written
permission of the other party or as such disclosure may be required by law.
Legend Merchant Group has been retained under this agreement as an independent
contractor with duties owed solely to the Company. The advice, written or oral,
rendered by Legend Merchant Group pursuant to this Agreement is intended solely
for the benefit and use of the Company in considering the matters to which this
agreement relates, and the Company agrees that such advice may not be relied
upon by any other person, used for any other purpose, reproduced, disseminated,
or referred to at any time, in any manner or for any purpose, nor shall any
public references to Legend Merchant Group be made by the Company, without the
prior written consent of Legend Merchant Group, which consent shall not be
unreasonably withheld.

      7.   Successors And Assigns. The benefits of this Agreement shall inure
to the parities hereto, their respective successors and assigns and to the
indemnified parties hereunder and their respective successors and assigns, and
the obligations and liabilities assumed in this Agreement shall be binding upon
the parties hereto and their respective successors and assigns. Notwithstanding
anything contained herein to the contrary, neither the Selling Dealer nor the
Company shall assign to an unaffiliated third party any of its obligations
hereunder.

      8.   Press Announcement. The Company agrees that Legend Merchant Group
shall, upon a successful transaction, have the right to place advertisements in
financial and other newspapers and journals at its own expense describing its
services to the Company hereunder.

      9.   Expenses. The Company will pay all of its costs relating to the
Placement contemplated hereby, including, without limitation, audit expenses,
issuance costs and taxes, counsel fees for the preparation of the Offering
Documents, filing fees and disbursements of counsel relating to the
qualification of the offered securities under federal securities laws, and legal
fees and expenses of counsel in connection with qualifying the offered
securities under sate blue sky laws. To the extent required by law, the Company
shall qualify the offered securities for offer and sale in those jurisdictions
designated by Legend Merchant Group. The Company's counsel shall be responsible
for state blue sky securities laws compliance by the Company.

                         QUANTRX BIOMEDICAL CORPORATION
      100 SOUTH MAIN STREET / SUITE 300 - DOYLESTOWN / PENNSYLVANIA - 18901
                      TEL: 267-880-1595 / FAX: 267-880-1596

<PAGE>

      10.  Conditions Of The Obligations Of Legend Merchant Group.

                  The obligations of Legend Merchant Group to act as agent
hereunder, to find purchasers for the Placement, and to attend and to deliver
documents at Closing shall be subject to the Thflowlng conditions;

                  (a) Between the date hereof and Closing, the Company and its
subsidiaries shall not have sustained any loss on account of fire, explosion,
flood, accident, calamity or other cause, of such character as materially
affects the business or property of the Company and its subsidiaries, whether or
not such loss is covered by insurance.

                  (b) Between the dare hereof and Closing, there shall be no
litigation instituted or threatened against the Company or any subsidiary (other
than as set forth in the Offering Document) and there shall be no proceeding
instituted or threatened before or by any federal or state commission,
regulatory body or administrative agency or other governmental body, domestic or
foreign. wherein an unfavorable ruling, decision or finding would materially
adversely affect the business, franchises, licenses, permits, operations or
financial condition or income of the Company.

                  (c) Except as contemplated herein or as set forth in the
Offering Document, during the period subsequent to the date hereof and prior to
Closing, the Company and each subsidiary: (i) shall have conducted its business
in the usual and ordinary manner as the saint was being conducted on the date
hereof, and (ii) except in the ordinary course of its business, the Company and
each subsidiary shall not have incurred any liabilities or obligations (direct
or contingent), or disposed of any assets, or entered into any material
transaction or suffered or experienced any substantially adverse change in its
condition, financial or otherwise, or in its working capital position. At
Closing, the capitalization of the Company shall be substantially the same as
set forth in the Offering Document.

                  (d) The authorization for the issuance and delivery of the
offered securities in the Placement and the Offering Document and related
materials, and for the execution and delivery of this Agreement, and all other
legal matters incident thereto, shall be reasonably satisfactory in all respects
to counsel for Legend Merchant Group.

                  (e) The representations and warranties of the Company made in
this Agreement or in any document or certificate delivered to Legend Merchant
Group pursuant hereto shall be true and correct on and as of the Closing with
the same force and effect as though such representations and warranties have
been made on and as of the Closing.

                         QUANTRX BIOMEDICAL CORPORATION
      100 SOUTH MAIN STREET / SUITE 300 - DOYLESTOWN / PENNSYLVANIA - 18901
                      TEL: 267-880-1595 / FAX: 267-880-1596

<PAGE>

                  f) The Company shall have performed and complied in all
material respects with all covenants, terms and agreements to be performed and
complied with by the Company on or before the Closing.

                  (g) The Company shall have provided such certificates as
Legend Merchant Group shall reasonably request.

                  (h) The Company and its President shall provide certificates
to Legend Merchant Group certifying that the proceeds of the Placement will be
used in accordance with the uses designated in "Use of Proceeds" in the Offering
Document.

                  (i) The Company shall have furnished a "Cold Comfort" letter
on and as of the Closing, in each case describing procedures carried out to a
date within five (5) days of the date of the letter, from independent public
accountants for the Company, substantially in the form approved by Legend
Merchant Group.

      11.  Indemnification

                  (a) The Company agrees to indemnify and hold harmless LEGEND
MERCHANT GROUP and each person, if any, who controls LEGEND MERCHANT GROUP
within the meaning of the 1933 Act or the 1934 Act (together. the "Acts"), the
LEGEND MERCHANT GROUP'S affiliated entities, partners, employees, legal counsel
and agents (the "DJ Indemnified Parties") against any losses, claims, damages,
obligations, penalties. judgments, awards, liabilities, costs, expenses and
disbursements (and any and all actions, suits, proceedings and investigations in
respect thereof and any and all legal and other costs, expenses and
disbursements in giving testimony or furnishing documents in response to a
subpoena or otherwise), joint or several, to which LEGEND MERCHANT GROUP or such
person may be subject, under the Acts or otherwise. including, without
limitation, the costs, expenses and disbursements, as and when incurred, of
investigating, preparing or defending any such action, suit, proceeding or
investigation (whether or nor in connection with litigation in which the LEGEND
MERCHANT GROUP is a party), directly or Indirectly, caused by, relating to,
based upon, arising out of. or in connection with (1) the violation or breach of
any representation, warranty or covenant or agreement of the Company set forth
in this Agreement or in any instrument, document, agreement or certificate
delivered by the Company In connection herewith; (ii) any untrue statement or
omission or any alleged untie statement or omission in the Offering Document or
selling material, excluding information contained in or omitted from the
Offering Document or selling material in reliance upon, and in conformity with,
information furnished to the Company by LEGEND MERCHANT GROUP or any
Participating Broker-Dealer specifically for use in preparation of the Offering
Document or selling material, as the case may be; (iii) any information provided
by or on behalf of Company in order to qualify or exempt the Offered Securities
for sale in any jurisdiction, or (iv) the failure of the Company to comply with
the provisions of the Acts and the regulations thereunder, including

                         QUANTRX BIOMEDICAL CORPORATION
      100 SOUTH MAIN STREET / SUITE 300 - DOYLESTOWN / PENNSYLVANIA - 18901
                      TEL: 267-880-1595 / FAX: 267-880-1596

<PAGE>

Regulation D; and will reimburse the Di Indemnified Parties for any legal or
other expenses reasonably incurred by the DJ Indemnified Parties in connection
with investigation of or defending against any such loss, claim, expense,
damage, liability, (or actions in respect thereof); provided, however, that the
Company shall not be required to indemnify the LMD Indemnified Parties for any
payment made to any claimant in settlement of any suitor claim unless such
payment is agreed to by the Company (which agreement shall nor be unreasonably
withheld) or by a court having jurisdiction of the controversy. This indemnity
agreement shall remain in full force and effect notwithstanding any
investigation made by LEGEND MERCHANT GROUP or on LEGEND MERCHANT GROUP'S behalf
shall survive consummation of the sale of the Offered Securities hereunder and
shall be in addition to any liability which the Company may otherwise have.

           (b) LEGEND MERCHANT GROUP agrees to indemnify and hold harmless the
     Company and each person, if any, who controls the Company within the
     meaning of the Acts, Company's affiliated entities, painters, employees,
     legal counsel and agents (the "Company Indemnified Parties") against any
     losses, claims, expenses, damages or liabilities (or actions in respect
     thereof), joint or several, to which the Company Indemnified Parties or any
     such controlling person may become subject, under the Acts or otherwise,
     insofar as such losses, claims, expenses, damages or liabilities (or
     actions in respect thereof) arise out of or are based upon any untrue
     statement or omission or any alleged untrue statement or omission in the
     Offering Document contained in or omitted from the Offering Document in
     reliance upon, and in conformity with, information furnished cc the Company
     by LEGEND MERCHANT GROUP or any Participating Broker-Dealer or either of
     them specifically for use in preparation of the Offering Document or
     selling material, as the case may be; and will reimburse the Company
     indemnified Parties for any legal or other expenses reasonably incurred by
     them in connection with investigating or defending against any such loss,
     claim, expense, damage, liability, (or actions in respect thereof);
     provided, however, that LEGEND MERCHANT GROUP shall not be required to
     indemnify the Company Indemnified Parties for any payment made to any
     claimant in settlement of any suit or claim unless such payment is approved
     by a court having jurisdiction over the controversy or LEGEND MERCHANT
     GROUP agrees to such settlement (which agreement shall not be unreasonably
     withheld): and provided further that LEGEND MERCHANT GROUP shall not be
     liable under this Section 11(b) for any losses, claims, expenses, damages
     or liabilities arising out of any act or failure to act on the part of any
     other person except LEGEND MERCHANT GROUP, its partners, employees and
     agents (including registered representatives) or any Participating
     Broker-Dealer. This indemnity agreement shall remain in full force anti
     effect notwithstanding any investigation made by or on behalf of the
     Company and shall survive consummation of the sale of the Offered
     Securities hereunder and the termination of this Agreement, and shall be in
     addition to any liability which LEGEND MERCHANT GROUP may otherwise have.
     Notwithstanding the foregoing, in no event shall the amount that the LEGEND

                         QUANTRX BIOMEDICAL CORPORATION
      100 SOUTH MAIN STREET / SUITE 300 - DOYLESTOWN / PENNSYLVANIA - 18901
                      TEL: 267-880-1595 / FAX: 267-880-1596

<PAGE>

     MERCHANT GROUP is required to indemnify the Company Indemnified Parties,
     exceed in the aggregate the compensation received by the LEGEND MERCHANT
     GROUP hereunder, except in the case of fraud on the part of the LEGEND
     MERCHANT GROUP.

            (c) The indemnified party shall notify the indemnifying party
     in writing promptly after the summons or other first legal process giving
     information of the nature of any and all claims which have been served upon
     the indemnified party. In case any action is brought against any
     indemnified party upon any such claim, the indemnifying party shall be
     entitled to participate at its own expense in the defense, or if it so
     elects, in accordance with arrangements satisfactory to any other
     indemnifying party or parties similarly notified, to assume the defense
     thereof, with counsel who shall be satisfactory to such indemnified party
     and other indemnified parties who are defendants in such action; and after
     notice from the indemnifying party to such indemnified party of its
     election so to assume the defense thereof and the retaining of such counsel
     by the indemnifying party, the indemnifying party shall not be liable to
     such indemnified party under this Section 11 for any legal or other
     expenses subsequently incurred by such indemnified party in connection with
     the defense thereof, other than the reasonable costs of investigation,
     unless the indemnified party shall have reasonably concluded that there are
     or may be defenses available to it which are different from or in addition
     to those available to the indemnifying party (in which case the
     indemnifying party shall not have the right to direct the defense of such
     action on behalf of the indemnified party), in any of which circumstances
     such expenses shall be borne by the indemnifying party.

      12.  Counterparts for the convenience of the parties, this Agreement may
be executed in any number of counterparts, each of which shall be and shall be
deemed to be, an original instrument, but all of which taken together shall
constitute one and the annie Agreement,

                         QUANTRX BIOMEDICAL CORPORATION
      100 SOUTH MAIN STREET / SUITE 300 - DOYLESTOWN / PENNSYLVANIA - 18901
                      TEL: 267-880-1595 / FAX: 267-880-1596

<PAGE>

      If the terms of our engagement as set forth in this letter are
satisfactory to you, please sign and date the enclosed copy of this letter and
indemnification form and send back to us. If this agreement is not executed by
both parties within five (5) days from its date, it shall cease to be a valid
offer to assist and represent the Company.

                                    Very truly yours,

                           By:      /s/ John H. Shaw III
                                    --------------------------------------------
                                    John H. Shaw III
                                    President & Co-Chairman
                                    Legend Merchant Group

ACCEPTED AND AGREED TO: as of the date hereof _____________, 2006

                                    For:

                           By:      /s/ Walter Witoshkin
                                    --------------------------------------------
                                    Walter Witoshkin
                                    Chief Executive Officer
                                    QuantRx Biomedical

                         QUANTRX BIOMEDICAL CORPORATION
      100 SOUTH MAIN STREET / SUITE 300 - DOYLESTOWN / PENNSYLVANIA - 18901
                      TEL: 267-880-1595 / FAX: 267-880-1596EXHIBIT 10.1

                                                           STRICTLY CONFIDENTIAL

            This AGREEMENT (this "Agreement") is entered into, as of April 2,
2007, by and between Criticare Systems, Inc., a Delaware corporation
("Criticare"), on the one hand, and BlueLine Catalyst Fund VII, L.P. ("BlueLine
Catalyst"), BlueLine Partners, L.L.C., a California limited liability company
and the sole general Partner of BlueLine Catalyst ("BlueLine California"),
BlueLine Capital Partners, L.P. ("BCP"), and BlueLine Partners, L.L.C., a
Delaware limited liability company and the sole general Partner of BCP
("BlueLine Partners"), and any affiliates (as defined under the Securities
Exchange Act of 1934, as amended (the "Exchange Act")) of any of the foregoing
(BlueLine Partners, BlueLine Catalyst, BlueLine California, BCP and any such
affiliate, collectively, "BlueLine"), on the other hand. Criticare and BlueLine
are sometimes referred to herein collectively as the "Parties" and individually
as a "Party."

            WHEREAS, on August 22, 2006, BlueLine announced that it would
commence a consent solicitation (the "First Consent Solicitation") to elect a
new majority of Criticare directors, and on September 12, 2006, BlueLine filed a
definitive consent solicitation statement with the Securities and Exchange
Commission ("SEC") soliciting written consents from holders of Criticare's
common stock, par value $0.04 per share (the "Common Stock"), of record as of
August 28, 2006, to: (1) repeal each provision of Criticare's By-laws (as
hereinafter defined) or amendment thereto adopted subsequent to March 13, 2006
and prior to the effectiveness of the Proposals (as defined below); (2) amend
Section 3.02 of Article III of Criticare's By-laws to provide that the entire
board of directors of Criticare will be elected each year; (3) remove all six of
the then present members of the Board and any person or persons elected or
designated by any such directors to fill any vacancy or newly created
directorship; (4) amend Section 3.01 of Article III of Criticare's By-laws to
fix the number of directors of Criticare at five; and (6) elect William Moore,
Cindy Collier, and Robert Munzenrider and re-elect Emil Soika and Sam Humphries
as directors of Criticare (collectively, the "Proposals");

            WHEREAS, on October 11, 2006, Criticare filed a definitive consent
revocation statement with the SEC urging its stockholders to reject the
Proposals, and on October 30, 2006, Criticare announced that BlueLine had failed
to deliver to Criticare by the applicable statutory deadline of October 27, 2006
the requisite number of written consents from Criticare's stockholders necessary
to effect the Proposals;

            WHEREAS, on November 20, 2006, BlueLine filed a preliminary consent
solicitation statement with the SEC soliciting written consents from holders of
the Common Stock of record as of November 17, 2006 to effect the Proposals (the
"Second Consent Solicitation");

            WHEREAS, Section 3.02 of Criticare's Restated By-Laws (as amended
through March 13, 2006) (the "By-laws") provides, among other things, that the
Board be divided

                                       1
<PAGE>

into three classes as nearly equal in number as may be, with a term of one class
expiring in each year, and that, at each annual meeting of stockholders, the
successors to the class of directors whose term shall then expire shall be
elected to hold office for a term expiring at the third succeeding annual
meeting;

            WHEREAS, Section 3.01 of the By-Laws provides that the number of
directors of Criticare shall be that number as the Board may establish but no
fewer than two (2) nor more than seven (7), and on January 26, 2006, the Board
set the number of directors of Criticare at six (6);

            WHEREAS, the Board currently consists of the following six
directors: Higgins D. Bailey, Ed.D (Chairman) and Sam B. Humphries, whose terms
expire at the 2007 annual meeting of stockholders of Criticare (sometimes
referred to herein as the "First Class Directors" or "First Class
Directorship"); Jeffrey T. Barnes (Vice Chairman) and N.C. Joseph Lai, Ph.D,
whose terms expire at the 2008 annual meeting of stockholders of Criticare
(sometimes referred to herein as the "Second Class Directors" or "Second Class
Directorship"); and Emil H. Soika and Stephen K. Tannenbaum (both of whom were
elected at Criticare's 2006 annual meeting of stockholders held on December 19,
2006), whose terms expire at the 2009 annual meeting of stockholders of
Criticare (sometimes referred to herein as the "Third Class Directors" or "Third
Class Directorship");

            WHEREAS, Criticare and BlueLine have each determined that it is in
their respective best interests and in the best interests of their stockholders
and/or investors, as applicable, that the Parties enter into this Agreement with
respect to the Second Consent Solicitation, the composition of the board of
directors of Criticare (the "Board") and certain related matters, as more fully
set forth herein; and

            WHEREAS, each of the initial BlueLine Nominees (as hereinafter
defined) has completed and furnished to Criticare Directors' & Officers'
Questionnaires, and the Parties have determined that (i) each such initial
BlueLine Nominee meets the standard for "independence" set forth in Section 121
of the AMEX Company Guide, and otherwise complies with the requirements of
Section 2(e) hereof, and (ii) one of the initial BlueLine Nominees (Robert
Munzenrider) is not affiliated with, and is not an "immediate family member" (as
such term is defined in Commentary .01 to Section 121 of the AMEX Company Guide)
of, BlueLine (the "Unaffiliated BlueLine Nominee").

            NOW, THEREFORE, in consideration of the foregoing, and the mutual
covenants, agreements, promises, releases and representations set forth herein,
the Parties agree as follows:

            1. Withdrawal of Second Consent Solicitation and Related Matters.

           (a) Immediately after execution and delivery of this Agreement by the
Parties (the "Effective Time"), and without further action by the Parties:

                                       2
<PAGE>

                      (i) any and all written consents purportedly delivered to
Criticare and/or its registered agent by BlueLine or any other Criticare
stockholder in connection with the Second Consent Solicitation, before, on or
after the Effective Time, including the written consent purportedly delivered by
BlueLine to Criticare on November 17, 2006 (collectively, the "Written
Consents"), shall, to the fullest extent permitted by law, be deemed null and
void, without force and effect, and withdrawn, and BlueLine agrees that it shall
not deliver any such Written Consents to Criticare in the manner required by
law; and

                      (ii) the Second Consent Solicitation shall be terminated
and, to the fullest extent permitted by law, be deemed null and void, without
force and effect, and withdrawn, with the same effect as if the Second Consent
Solicitation had never been initiated, and BlueLine agrees that it shall, and
shall cause its directors, officers, employees, agents and representatives to,
take any and all lawful actions, as may be necessary or advisable under the
Exchange Act and the rules and regulations promulgated thereunder, to cause the
Second Consent Solicitation to be terminated and, to the fullest extent
permitted by law, be deemed null and void, without force and effect, and
withdrawn, with the same effect as if the Second Consent Solicitation had never
been initiated.

            (b) BlueLine covenants and agrees that (i) it shall not, without
Criticare's prior written consent, disclose to any third party, directly or
indirectly, any information relating to the final or any intermediate tally of
written consents with respect to the First Consent Solicitation or the Second
Consent Solicitation, unless so required under applicable law (provided that, to
the extent permitted by law, it shall notify Criticare in writing as early as
possible in advance of such disclosure), (ii) it shall cause its directors,
officers, employees, agents and representatives to comply with such prohibition,
and (iii) within two business days after the Effective Time, it shall cause all
Written Consents in its possession or under its control to be destroyed and will
provide a written certification to Criticare that such action has been taken.

            2. Board Representation and Related Matters.

            (a) To the fullest extent permitted by law, Criticare shall:

                       (i) cause Jeffrey T. Barnes to resign his Second Class
Directorship, which resignation shall be effective immediately prior to the
Effective Time;

                       (ii) cause the number of directors constituting the whole
Board to be increased from six (6) to seven (7), which increase shall be
effective immediately prior to the Effective Time, and the additional director
seat shall be allocated to the Third Class Directors such that the Third Class
Directors shall consist of three members;

                       (iii) cause the Board to fill the vacancy in the Third
Class Directorship created by the aforesaid increase with Jeffrey T. Barnes,
which filling of

                                       3
<PAGE>

such vacancy shall be effective immediately prior to the Effective Time and
immediately following the resignation of Jeffrey T. Barnes pursuant to clause
(i);

                       (iv) cause Stephen K. Tannenbaum to resign his Third
Class Directorship, which resignation shall be effective at the Effective Time;
and

                       (v) cause the Board to (x) fill the vacancy in the Third
Class Directorship created by the resignation of Stephen K. Tannenbaum with
William Moore, such that William Moore shall become a Third Class Director, and
(y) (subject to the other provisions of this Section 2) fill the vacancy in the
Second Class Directorship created by the resignation of Jeffrey T. Barnes with
Robert Munzenrider, such that Robert Munzenrider shall become a Second Class
Director, in each case effective as of the Effective Time, such that, at the
Effective Time (and immediately following the resignation of Stephen K.
Tannenbaum), the Board shall consist of the following directors in the following
classes:

                  First Class Directors:

                  (1) Higgins D. Bailey, Ed.D (Chairman)
                  (2) Sam B. Humphries

                  Second Class Directors:

                  (3)  N.C. Joseph Lai, Ph.D
                  (4)  Robert Munzenrider

                  Third Class Directors:

                  (5) Jeffrey T. Barnes (Vice Chairman)
                  (6) William Moore
                  (7) Emil H. Soika

William Moore and Robert Munzenrider (together with any alternative nominee(s)
nominated by BlueLine in accordance with this Section 2) are referred to herein
together as the "BlueLine Nominees" and individually as a "BlueLine Nominee."
The Parties agree, to the fullest extent permitted by law and notwithstanding
anything to the contrary contained in the first sentence of Section 3.10 of the
By-laws, if any, that any directors chosen in accordance with this Section 2(a)
shall hold office until the next election of the class for which such directors
shall have been chosen, and until their successors shall be elected and
qualified. BlueLine further agrees, to the fullest extent permitted by law and
notwithstanding anything to the contrary contained in the last sentence of
Section 3.10 of the By-laws or Section 223(c) of the General Corporation Law of
the State of Delaware, if any, that it shall not, and shall cause its directors,
officers, employees, agents and representatives not to, apply to the Court of
Chancery of the State of Delaware to summarily order an election of directors of
Criticare to fill the vacancies created or provided for in this Agreement.

                                       4
<PAGE>

            (b) From and after the Effective Time and until the 30th day prior
to Criticare's 2009 annual stockholders meeting (the "Agreed Period"), if any of
the BlueLine Nominee(s) then serving as Criticare director(s) shall no longer be
able to serve as director(s) for any reason whatsoever, to the fullest extent
permitted by law, BlueLine shall have the right (and Criticare shall do all
lawful things reasonably necessary) to cause the Board to fill any vacancy
caused by the resignation of the BlueLine Nominee(s) as aforesaid, with one or
more alternative individuals nominated by BlueLine and meeting the criteria set
forth in this Section 2(b); provided, however, that BlueLine's right to fill
such vacancy or vacancies with one or more alternative BlueLine Nominee(s) shall
be subject in all respects to BlueLine's beneficial ownership (within the
meaning of Rule 13d-3 of the SEC) of Criticare Common Stock remaining above (x)
1,106,827 shares (which number shall be subject to adjustment to the extent of
any reclassification, stock dividend, stock split or combination,
recapitalization or similar transaction) (the "9.0% Ownership Threshold"), in
order for BlueLine to have the right to have up to two alternative BlueLine
Nominees (one of whom shall be an Unaffiliated BlueLine Nominee) appointed to
the Board, and (y) 614,904 shares (which number shall be subject to adjustment
to the extent of any reclassification, stock dividend, stock split or
combination, recapitalization or similar transaction) (the "5% Ownership
Threshold"), in order for BlueLine to have the right to have up to one
alternative BlueLine Nominee (who shall be an Unaffiliated BlueLine Nominee)
appointed to the Board, as more fully set forth in this Section 2. Any such
alternative BlueLine Nominee(s) must be reasonably acceptable to Criticare's
Nominating and Corporate Governance Committee; provided, however, that each
alternative BlueLine Nominee shall meet the standard for "independence" set
forth in Section 121 of the AMEX Company Guide and otherwise comply with the
requirements of Section 2(e) hereof to the extent applicable.

            (c) The Parties acknowledge and agree that, notwithstanding anything
in this Agreement to the contrary, (i) at no time after the Effective Time,
shall Criticare have any obligation to nominate any BlueLine Nominees for
re-election to the Board at any Criticare annual or special stockholders meeting
(or in connection with any stockholder consent in lieu of any such meeting), and
(ii) after the expiration of the Agreed Time, Criticare shall not be obligated
to take any action or do any thing to cause any individuals nominated by
BlueLine to be nominated or appointed to the Board or elected at any Criticare
annual or special stockholders meeting, or to fill any vacancy created by the
death, resignation, disqualification or removal of any one or more of the
BlueLine Nominee(s).

            (d) In furtherance of the other provisions of this Section 2:

                       (i) on or before the Effective Date or on or before the
filling of any vacancies as provided in Section 2(b), BlueLine shall procure
from any BlueLine Nominee who is not an Unaffiliated BlueLine Nominee, such
director's irrevocable written resignation from the Board, conditioned upon, and
effective immediately upon, BlueLine's beneficial ownership (determined as set
forth above) of outstanding Common Stock dropping below the 9.0% Ownership
Threshold, which resignation shall provide

                                       5
<PAGE>

that (x) the Board can, within ten (10) business days after receipt of the
notice provided for in Section 4(a), accept or reject such resignation in its
sole discretion, and (y) if the Board does not act to accept such resignation
within such period, such resignation will expire and thereafter become null and
void. Following BlueLine's beneficial ownership (determined as set forth above)
of outstanding Common Stock dropping below the 9.0% Ownership Threshold,
BlueLine's right to nominate any BlueLine Nominee who is not an Unaffiliated
BlueLine Nominee shall immediately terminate. BlueLine covenants and agrees that
it shall take all lawful actions, if any, necessary or advisable to give effect
to the resignation of any such BlueLine Nominee that has been accepted by the
Board; and

                       (ii) BlueLine's right to nominate any BlueLine Nominee to
fill any vacancy caused by the inability of such BlueLine Nominee to continue to
serve as director for any reason whatsoever, as provided in Section 2, shall
immediately terminate upon BlueLine's beneficial ownership (determined as set
forth above) of outstanding Common Stock dropping below the 5% Ownership
Threshold.

            (e) BlueLine shall cause each BlueLine Nominee (i) who is not an
Unaffiliated BlueLine Nominee to comply with all duly authorized lawful policies
and practices of the Board (and any committee thereof of which such BlueLine
Nominee may be a member), now in effect or hereinafter duly adopted by, and
provided to, the Board, and (ii) to provide Criticare with completed Directors'
& Officers' Questionnaires, in a form which Criticare shall provide and which
form of questionnaire Criticare ordinarily uses, in accordance with Board policy
and practice as applicable to all directors. In addition, the Parties hereby
acknowledge and agree that, notwithstanding anything in this Agreement to the
contrary, the exercise by the Board or any committee thereof, or any member of
the foregoing (in his capacity as such), of its or his fiduciary duties or
obligations under applicable law, shall not constitute a breach of this
Agreement.

            (f) Criticare covenants and agrees that, during the Agreed Period,
it shall not (i) convene a regular or special meeting of the Board or of any
committee of the Board on which any BlueLine Nominee then serves without
providing advance notice, in accordance with the relevant provisions of the
By-laws and/or such committee's charter, of such meeting to, or obtaining a
waiver thereof from, the applicable BlueLine Nominee, and which notice, in any
event, shall be the same notice as provided to all directors, and (ii) without
the approval of the Unaffiliated BlueLine Nominee (x) increase the size of the
Board, (y) create an Executive Committee of the Board (or any other committee
that would have general Board power and authority like an Executive Committee),
or (z) create any other committees of the Board, except any such committees that
are required by law or under applicable listing standards or that the Board,
advised by outside counsel, deems it advisable to create under applicable
Delaware law.

            (g) As of the Effective Time, the Board shall fill the vacancy on
the Audit Committee of the Board created by the resignation of Stephen K.
Tannenbaum with Robert Munzenrider and designate Robert Munzenrider as the
Chairman of such Audit Committee; provided, however, that Mr. Munzenrider's
continued service as a member and Chairman of the Audit Committee shall be
subject to his continuing to qualify as an

                                       6
<PAGE>

Unaffiliated BlueLine Nominee and to meet any and all applicable qualifications
for service on such committee (including as set forth in such Audit Committee's
charter, the rules and regulations of the SEC and any applicable listing
standards in effect from time to time).

            (h) Subject to the other provisions of this Agreement, the BlueLine
Nominees shall have and be entitled to exercise the same powers, protections,
obligations and compensation as other directors of Criticare, and shall have
such rights provided to, and obligations required by, directors of a Delaware
corporation under Delaware law. Without limiting the foregoing, at the Effective
Time, Criticare shall add the BlueLine Nominees to Criticare's existing
Directors' and Officers' Insurance Policy and (if applicable) enter into
indemnification agreements with the BlueLine Nominees in form and substance
identical to the indemnification agreements (if any) entered into with other
Board members (who are not also officers or employees of Criticare).

            3. Standstill. Subject to the last paragraph of this Section 3,
BlueLine covenants and agrees that during the Agreed Period, unless specifically
requested in writing in advance by a majority of the Board (excluding any
BlueLine Nominee who is not an Unaffiliated BlueLine Nominee), BlueLine shall
not, and shall cause its directors, officers, employees, agents, representatives
and affiliates not to, directly or indirectly, assist (including by providing
information or financing), encourage or participate with others to:

            (a) acquire, announce an intention to acquire, offer, seek or
propose to acquire, or agree to acquire, directly or indirectly, by purchase,
gift, tender or exchange offer, or otherwise, beneficial or record ownership of
any shares of Common Stock or any other voting securities of Criticare or any of
its subsidiaries, including any rights, warrants, options or other securities
convertible into or exchangeable for such shares or other voting securities, or
any assets of Criticare or any division or subsidiary thereof, from Criticare
stockholders, Criticare or third parties; provided, however, that nothing in
this Section 3(a) shall be deemed to limit, restrict or prevent BlueLine from
acquiring additional shares of Common Stock in an aggregate amount that, when
added to all shares then beneficially owned (within the meaning of Rule 13d-3 of
the SEC) by BlueLine, do not exceed 14.9% of the then-outstanding shares of
Common Stock (the "Maximum Ownership Threshold");

            (b) form, join or in any way engage in discussions relating to the
formation of, or participate in, a "group" within the meaning of Section
13(d)(3) of the Exchange Act with respect to shares of Common Stock or any other
voting securities of Criticare, or any of the matters covered by this Section,
or otherwise act in concert with any Person (as hereinafter defined) in respect
of any such shares or voting securities or matters;

            (c) arrange, or in any way participate in, any financing for the
purchase by any individual, corporation, partnership, limited liability company,
limited partnership, limited liability partnership, syndicate, person, trust,
association,

                                       7
<PAGE>

organization or other entity, including any successor, by merger or otherwise,
of any of the foregoing (collectively, "Persons" and each, a "Person"), of any
shares of Common Stock or any other voting securities or assets or businesses of
Criticare or any of its affiliates;

            (d) join in or in any way participate in any pooling agreement,
stockholders agreement, voting trust or other arrangement or agreement with
respect to the voting of any shares of Common Stock or other voting securities
of Criticare;

            (e) make, seek to propose or participate in making an offer or
proposal to Criticare, Criticare's stockholders or any third party (by public
announcement, submission to Criticare, such stockholders or third party or
otherwise) in respect of any extraordinary corporate transaction involving
Criticare, its Common Stock or other voting securities or the capital stock or
voting securities of any of its affiliates, including by merger, consolidation,
tender or exchange offer, reorganization, recapitalization, extraordinary
dividend, dissolution, restructuring, liquidation, sale or transfer of assets
(other than in the ordinary course of Criticare's business) or otherwise, or the
acquisition or purchase by BlueLine or any other Person of all or any portion of
the assets or shares of Common Stock or other voting securities of Criticare or
the capital stock or voting securities of any of its affiliates, including by
merger, consolidation, tender or exchange offer, reorganization,
recapitalization, extraordinary dividend, dissolution, restructuring,
liquidation, sale or transfer of assets (other than in the ordinary course of
Criticare's business) or otherwise;

            (f) (i) solicit proxies or consents for the voting of any Common
Stock or other voting securities of Criticare or any of its subsidiaries or
otherwise become a "participant," directly or indirectly, in any "solicitation"
of "proxies" or consents to vote, or become a "participant" in any "election
contest" involving Criticare, or its Common Stock or other voting securities, or
such subsidiary (all terms used herein and defined in Regulation 14A under the
Exchange Act having the meanings assigned to them therein), including by any
means allowed by or pursuant to the "e-proxy" amendments to the proxy rules
adopted or proposed by the SEC on December 13, 2006, (ii) call or seek to call,
directly or indirectly, any special meeting of stockholders of Criticare for any
reason whatsoever, (iii) seek, request, or take any action to obtain or retain,
directly or indirectly, any list of holders of Common Stock or any voting or
other securities of Criticare or to obtain or retain, directly or indirectly,
the books and records of Criticare or its affiliates, (iv) seek to advise or
influence any Person with respect to the voting of Common Stock or any other
voting securities of Criticare or any of its subsidiaries, (v) initiate, propose
or otherwise "solicit" Criticare stockholders for the approval of shareholder
proposals, whether made pursuant to Rule 14a-8 or Rule 14a-4 under the Exchange
Act, or otherwise, (vi) otherwise communicate with Criticare's stockholders or
holders of voting securities of Criticare or any of its subsidiaries pursuant to
Rule 14a-1(l)(2)(iv) under the Exchange Act, (vii) participate in, or take any
action pursuant to, any "shareholder access" proposal which may be adopted by
the SEC whether in accordance with previously proposed Rule 14a-11 or otherwise,
(vii) otherwise engage in any course of conduct with the purpose of causing
other stockholders of Criticare or the holders of

                                       8
<PAGE>

voting securities of Criticare to vote contrary to the recommendation of the
Board on any matter presented to Criticare's stockholders or holders of voting
securities of Criticare for their vote or challenging the policies of Criticare,
or (viii) otherwise act, alone or in concert with others, to seek to control or
influence the management, the Board, policies or affairs of Criticare or any of
its subsidiaries (it being understood that this clause (iii) shall not limit the
exercise of the powers, protections and obligations of the BlueLine Nominee(s)
as director(s) of Criticare under Delaware law);

            (g) except as permitted by this Agreement, propose any change in the
composition or classification of the Board or management of Criticare, including
any plans or proposals to change the number or term of directors or fill any
vacancies on the Board;

            (h) seek to change Criticare's certificate of incorporation or
By-laws or Criticare's business or corporate structure (it being understood that
the foregoing provisions of this subsection (h) shall not limit the exercise of
the powers, protections and obligations of the BlueLine Nominee(s) as
director(s) of Criticare under Delaware law) or otherwise take any action
inconsistent with the ownership of shares of Common Stock or any other voting
securities of Criticare solely for the purpose of investment;

            (i) (i) make or disclose any statement regarding any intent,
purpose, plan or proposal with respect to the Board, Criticare, its management,
policies or affairs or any of its Common Stock, securities or assets or those of
its affiliates or this Agreement that is inconsistent with the provisions of
this Agreement, including a request (by submission to Criticare, public
announcement or otherwise) in any form that the prohibitions set forth in this
Agreement be waived or that Criticare take any action which would permit
BlueLine to take any of the actions prohibited by this Agreement, (ii) otherwise
seek in any fashion, directly or indirectly, a waiver, amendment or modification
of any provision of this Agreement or make any statement (to Criticare or a
third party or by public announcement) relating to BlueLine's willingness to
pursue any such prohibited action conditioned upon waiver, amendment or
modification of any provision of this Agreement, or (iii) take any action that
could require Criticare to make any public disclosure relating to any such
intent, purpose, plan, proposal or condition; and

            (j) (i) initiate, solicit, encourage, advise, assist, facilitate,
finance, or otherwise participate with, any other Person in the taking by such
Person of any of the foregoing actions, (ii) make any investments in any Person
that engages, or offers or proposes to engage, in any of the foregoing, or (iii)
otherwise enter into any discussions, negotiations, arrangements or
understandings with any Person with respect to any of the foregoing actions.

BlueLine shall promptly advise Criticare of any inquiry or proposal made to
BlueLine or any of its affiliates or representatives with respect to any of the
foregoing.

            4. Limitations on Standstill. Notwithstanding any other provision of
this Agreement to the contrary, nothing in Section 3 shall (a) prevent BlueLine
from selling

                                       9
<PAGE>

shares of Common Stock or purchasing Common Stock up to the Maximum Ownership
Threshold, provided that in each such case BlueLine shall promptly (but not
later than the earlier of (i) any public disclosure thereof and (ii) one
business day after such sale or purchase) notify Criticare in writing of any
such sale or purchase, (b) limit the BlueLine Nominees (during the term of their
service as directors of Criticare) from taking any action in their capacity as
directors of Criticare and/or complying with their fiduciary duties as directors
of Criticare, or (c) prevent BlueLine from voting the shares of Common Stock
owned by it on the record date for such action in its discretion, provided
BlueLine is otherwise in compliance with the provisions of Section 3.

            5. Mutual Release and Waiver.

            (a) To the fullest extent permitted by law, BlueLine (for itself,
its directors, officers, employees, agents, representatives, affiliates, heirs,
successors, assigns, executors and/or administrators) does hereby and forever
release and discharge Criticare and its directors, officers, employees, agents,
attorneys, partners, stockholders, representatives and affiliates, past or
present, and any successors or assigns thereof (each, a "Criticare Person"),
from any and all causes of action, actions, judgments, liens, debts, contracts,
indebtedness, damages, losses, claims, liabilities, rights, interests and
demands of whatsoever kind or character (other than fraud), known or unknown,
suspected to exist or not suspected to exist, anticipated or not anticipated,
whether or not heretofore brought before any state or federal court, which
BlueLine has or may have against any Criticare Person by reason of any and all
acts, omissions, events or facts occurring or existing prior to the Effective
Time, including all claims arising under contract, tort, common law, or any
federal, state or other governmental law, statute, regulation or ordinance or
common law, excepting only those obligations expressly required to be performed
hereunder.

            (b) To the fullest extent permitted by law, Criticare (for itself,
its directors, officers, employees, agents, representatives, affiliates, heirs,
successors, assigns, executors and/or administrators) does hereby and forever
release and discharge BlueLine and its directors, officers, employees, agents,
attorneys, partners, stockholders, representatives and affiliates, past or
present, and any successors or assigns thereof (each, a "BlueLine Person"), from
any and all causes of action, actions, judgments, liens, debts, contracts,
indebtedness, damages, losses, claims, liabilities, rights, interests and
demands of whatsoever kind or character (other than fraud), known or unknown,
suspected to exist or not suspected to exist, anticipated or not anticipated,
whether or not heretofore brought before any state or federal court, which
Criticare has or may have against any BlueLine Person by reason of any and all
acts, omissions, events or facts occurring or existing prior to the Effective
Time, including, all claims arising under contract, tort, common law, or any
federal, state or other governmental law, statute, regulation or ordinance or
common law, excepting only those obligations expressly required to be performed
hereunder.

            (c) Except for those obligations created by or arising out of this
Agreement and except as limited in this Agreement, it is the intention of
BlueLine and Criticare in executing this Agreement that the same shall be
effective as a bar to each and

                                       10
<PAGE>

every claim, demand and cause of action hereinabove specified. In furtherance of
this intention and to the fullest extent permitted by law, BlueLine and
Criticare hereby expressly and mutually consent that this Agreement shall be
given full force and effect according to each and all of its express terms and
provisions, including those related to unknown and unsuspected claims, demands
and causes of action, if any, as well as those relating to any other claims,
demands and causes of action hereinabove specified.

            (d) BlueLine and Criticare acknowledge that each Party may hereafter
discover claims or facts in addition to or different from those which each Party
now knows or believes to exist with respect to the subject matter of this
Agreement and which, if known or suspected at the time of executing this
Agreement, may have materially affected this Agreement. To the fullest extent
permitted by law, BlueLine and Criticare hereby waive any right, claim or cause
of action that might arise as a result of such different or additional claims or
facts (other than rights, claims or other causes of action arising out of
fraud).

            6. Mutual Non-Disparagement. Each of the Parties covenants and
agrees that none of it or its respective subsidiaries, officers, employees or
directors shall in any way knowingly disparage, attempt to discredit, or
otherwise call into disrepute, the other Party or such other Party's
subsidiaries, officers, directors or employees, or any of its products or
services, in any manner that would damage the business or reputation of such
other Party, its products or services or its subsidiaries, officers, directors
or employees. Without limiting the foregoing, except as required by law
(including the rules and regulations of the SEC and applicable listing
standards), neither Party shall make any comments or statements to the press,
investors (including stockholders of Criticare), analysts, government entities
(including the SEC), or any individual or entity with whom the other Party has a
business relationship or any other Person, if such comment or statement would
reasonably be expected to adversely affect the business or reputation of such
other Party or any of its products or services or any of its subsidiaries,
officers, directors or employees.

            7. Non-Solicitation. During the Agreed Period, BlueLine shall not,
directly or indirectly, either on BlueLine's own behalf or on behalf of any
other Person, encourage, facilitate or attempt to persuade or solicit any Person
who is an officer of, employee of, or consultant, independent contractor or
other supplier or vendor for, Criticare, (i) to terminate or materially and
adversely alter such employment, consulting, independent contractor or supplier
or vendor relationship, (ii) to take any action against, or that would
materially and adversely affect, Criticare, the Board or Criticare' current
management, or (iii) to use any confidential information relating to Criticare
or its business for the benefit of any Person other than Criticare.

            8. Confidentiality. Any information obtained by either Party
relating to the other Party as a result, directly or indirectly, of the entering
into and performance of this Agreement (collectively, the "Confidential
Information") shall be kept confidential by the Party receiving such
Confidential Information (the "Receiving Party") and shall not, directly or
indirectly, be misappropriated, disclosed, copied, used, reproduced, sold

                                       11
<PAGE>

or made available to any third party at any time without the express written
consent of the Party disclosing such Confidential Information (the "Disclosing
Party"). Notwithstanding the foregoing, Confidential Information does not
include information (i) that is or becomes generally available to the public
other than as a result of an act or omission by the Receiving Party or as a
result of the breach of this Agreement by the Receiving Party, (ii) that the
Receiving Party receives on a non-confidential basis from a source other than
the Disclosing Party or any of its current or former officers, directors,
employees, consultants, stockholders, agents, representatives or affiliates,
provided such source is not subject to a contractual, legal, fiduciary or other
obligation of confidentiality with respect to such information, or (iii) that
the Receiving Party is required by applicable law to disclose; provided that,
the Receiving Party promptly shall notify the Disclosing Party in the event the
Receiving Party is required by applicable law to disclose any Confidential
Information.

            8. Public Announcements. Immediately after the Effective Time, the
Parties shall issue a joint press release in the form attached hereto as Exhibit
A (the "Press Release"). Thereafter, except as required by law, none of the
Parties shall issue or make any statements, public or otherwise, regarding this
Agreement, its terms, the obligations of the Parties hereunder, or any other
matters discussed in the Press Release, which statements are inconsistent with
such Press Release.

            9. Expenses.

            (a) Except as otherwise provided in this Section 9, the Parties
shall bear their own expenses related to the First Consent Solicitation or the
Second Consent Solicitation and the preparation, negotiation and delivery of
this Agreement.

            (b) As reimbursement for a portion of the expenses incurred by
BlueLine related to the First Consent Solicitation, Second Consent Solicitation,
the negotiation of this Agreement and related matters, Criticare agrees as
follows: On or prior to 10 business days after the Effective Time, and provided
that Criticare has received from BlueLine written documentation of reasonable
and actual out-of-pocket expenses incurred by BlueLine in connection therewith,
Criticare shall pay to BlueLine (by wire transfer in immediately available funds
to an account designated in writing by BlueLine at least three days in advance
thereto) $20,000.00 in cash.

            10. Representations and Warranties. Each of the Parties hereby
represents and warrants to the other Party that:

            (a) it is duly organized, validly existing and in good standing
under the laws of the state of its jurisdiction or organization;

            (b) it has full power, authority and legal right to execute and
deliver this Agreement and to perform its obligations hereunder, all of which
have been duly authorized by all requisite corporate, partnership or limited
liability company action, as the case may be; and

                                       12
<PAGE>

            (c) this Agreement has been duly and validly executed and delivered
by such Party and constitutes the legal, valid and binding obligation of such
Party, enforceable against it in accordance with its terms, except as
enforcement may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting creditors' rights generally and by general
principles of equity (regardless of whether considered in a proceeding in equity
or at law).

            11. Miscellaneous Provisions.

            (a) This Agreement and all disputes or controversies arising out of
or relating to this Agreement or the obligations of the Parties hereunder shall
be governed by, and construed in accordance with, the internal laws of the State
of Delaware, without regard to the laws of any other jurisdiction that might be
applied because of the conflict of laws principles of the State of Delaware.

            (b) To the fullest extent permitted by law, each of the Parties
irrevocably agrees that any legal action or proceeding arising out of or
relating to this Agreement or for recognition and enforcement of any judgment in
respect hereof brought by the other Party or its successors or assigns shall be
brought and determined in a state or federal court sitting in New Castle County,
Delaware, and each of the Parties hereby irrevocably submits to the co-exclusive
jurisdiction of the aforesaid courts for itself and with respect to its
property, generally and unconditionally, with regard to any such action or
proceeding arising out of or relating to this Agreement and the obligations of
the Parties hereunder (and agrees not to commence any action, suit or proceeding
relating thereto except in such courts, except to enforce judgments rendered by
such state or federal courts; such actions to enforce a Delaware judgment may be
brought in any court of competent jurisdiction). To the fullest extent permitted
by law, each of the Parties further agrees to accept service of process in any
manner permitted by such courts. To the fullest extent permitted by law, each of
the Parties hereby irrevocably and unconditionally waives, and agrees not to
assert, by way of motion or as a defense, counterclaim or otherwise, in any
action or proceeding arising out of or relating to this Agreement or the
obligations of the Parties hereunder, (a) any claim that it is not personally
subject to the jurisdiction of the above-named courts for any reason, (b) that
it or its property is exempt or immune from jurisdiction of any court anywhere
or from any legal process commenced in such courts (whether through service of
notice, attachment prior to judgment, attachment in aid of execution of
judgment, execution of judgment or otherwise), (c) that the suit, action or
proceeding in any such court is brought in an inconvenient forum, (d) that the
venue of such suit, action or proceeding is improper or (e) that this Agreement,
or the subject matter hereof, may not be enforced in or by such courts.

            (c) Neither this Agreement nor any of the rights, interests or
obligations under this Agreement may be assigned or delegated, in whole or in
part, by operation of law or otherwise, by any of the Parties without the prior
written consent of the other Parties, and any such assignment without such prior
written consent shall, to the fullest

                                       13
<PAGE>

extent permitted by law, be null and void. Subject to the preceding sentence,
this Agreement will be binding upon, inure to the benefit of, and be enforceable
by, the Parties and their respective successors and assigns.

            (d) This Agreement may not be amended, modified or supplemented in
any manner, whether by course of conduct or otherwise, except by an instrument
in writing signed on behalf of each Party and otherwise as expressly set forth
herein.

            (e) No failure or delay of any of the Parties in exercising any
right or remedy hereunder shall operate as a waiver thereof, nor shall any
single or partial exercise of any such right or power, or any abandonment or
discontinuance of steps to enforce such right or power, or any course of
conduct, preclude any other or further exercise thereof or the exercise of any
other right or power. The rights and remedies of the Parties hereunder are
cumulative and are not exclusive of any rights or remedies which they would
otherwise have hereunder. Any agreement on the part of any of the Parties to any
such waiver shall be valid only if set forth in a written instrument executed
and delivered by a duly authorized officer on behalf of such Party.

            (f) Nothing in this Agreement, express or implied, is intended to or
shall confer upon any Person other than the Parties and their respective
successors and permitted assigns any legal or equitable right, benefit or remedy
of any nature under or by reason of this Agreement.

            (g) This Agreement constitutes the entire agreement, and supersedes
all prior written agreements, arrangements, communications and understandings
and all prior and contemporaneous oral agreements, arrangements, communications
and understandings among the Parties with respect to the subject matter of this
Agreement. Notwithstanding any oral agreement of the Parties or their
representatives to the contrary, no Party to this Agreement shall be under any
legal obligation to enter into or complete the matters contemplated hereby
unless and until this Agreement shall have been executed and delivered by each
of the Parties.

            (h) The Parties agree that irreparable damage would occur in the
event that any of the provisions of this Agreement were not performed in
accordance with their specific terms or were otherwise breached (a "Breach").
Accordingly, the Parties agree that the non-breaching Party shall be entitled,
to the fullest extent permitted by law, to specific performance of the terms
hereof, including an injunction or injunctions to prevent breaches of this
Agreement and to enforce specifically the terms and provisions of this Agreement
in any state or federal court sitting in New Castle County, Delaware, this being
in addition to any other remedy to which such non-breaching Party may be
entitled at law or in equity. Each of the Parties further hereby waives, to the
fullest extent permitted by law, (a) any defense in any action for specific
performance that a remedy at law would be adequate and (b) any requirement under
any law to post security as a prerequisite to obtaining equitable relief. In
addition, each of the Parties agrees that in the event of a Breach by such
Party, the non-breaching Party shall be entitled to payment by the breaching
Party of any expenses, including the reasonable fees and expenses of

                                       14
<PAGE>

legal counsel, that such non-breaching Party may incur in connection with its
enforcement of the provisions of this Agreement.

            (i) Whenever possible, each provision or portion of any provision of
this Agreement shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision or portion of any provision of this
Agreement is held to be invalid, illegal or unenforceable in any respect under
any applicable law or rule in any jurisdiction, such invalidity, illegality or
unenforceability shall not affect any other provision or portion of any
provision in such jurisdiction, and this Agreement shall be reformed, construed
and enforced in such jurisdiction as if such invalid, illegal or unenforceable
provision or portion of any provision had never been contained herein.

            (j) TO THE FULLEST EXTENT PERMITTED BY LAW, THE PARTIES TO THIS
AGREEMENT HEREBY IRREVOCABLY WAIVE ALL RIGHT TO A TRIAL BY JURY IN ANY ACTION,
PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE
OBLIGATIONS OF EACH OF THE PARTIES HEREUNDER.

            (k) All notices and other communications hereunder shall be in
writing and shall be deemed duly given (a) on the date of delivery if delivered
personally, or if by facsimile, upon written confirmation of receipt by
facsimile or otherwise, (b) on the first business day following the date of
dispatch if delivered utilizing a next-day service by a recognized next-day
courier or (c) on the earlier of confirmed receipt or the fifth business day
following the date of mailing if delivered by registered or certified mail,
return receipt requested, postage prepaid. All notices hereunder shall be
delivered to the addresses set forth below, or pursuant to such other
instructions as may be designated in writing by the Party to receive such
notice:

                  if to Criticare to:

                       Criticare Systems, Inc.
                       20925 Crossroads Circle, Suite 100
                       Waukesha, Wisconsin 53186
                       Attention:  Emil Soika
                       Facsimile:  (262) 798-8728

                  with a copy (which shall not constitute notice) to:

                       Greenberg Traurig LLP
                       200 Park Avenue
                       New York, New York 10166
                       Attention:  Lorenzo Borgogni, Esq.
                       Facsimile:  (212) 801-6400

                                       15
<PAGE>

                  if to BlueLine to:

                       BlueLine Partners, LLC
                       4115 Blackhawk Plaza Circle, Suite 100
                       Danville, CA 94506
                       Attention:  Scott A. Shuda
                       Facsimile:  (925) 648-2086

                  with a copy (which shall not constitute notice) to:

                       Nelson Mullins Riley & Scarborough LLP
                       999 Peachtree Street, 14th Floor
                       Atlanta, Georgia  30309-3964
                       Attention:  Steven L. Berson
                       Facsimile:  (404) 817-6050

            (l) When a reference is made in this Agreement to a Section of this
Agreement, such reference shall be to a Section of this Agreement unless
otherwise indicated. The headings contained in this Agreement are for
convenience of reference purposes only and shall not affect in any way the
meaning or interpretation of this Agreement. All words used in this Agreement
will be construed to be of such gender or number as the circumstances require.
The word "including," and words of similar import when used in this Agreement
will mean "including, without limitation," unless otherwise specified. No
provision of this Agreement shall be construed against or interpreted to the
disadvantage of either Party hereto by any court or other governmental or
judicial authority by reason of such Party having or being deemed to have
structured or dictated such provision. Each Party hereto acknowledges that it
has had the benefit of legal counsel of its own choice and has been afforded an
opportunity to review this Agreement with its legal counsel and that this
Agreement shall be construed as if jointly drafted by the Parties.

            (m) Each of the Parties acknowledges that each Party to this
Agreement has been represented by counsel in connection with this Agreement and
the obligations of each of the Parties hereunder. Accordingly, any rule of law
or any legal decision that would require interpretation of any claimed
ambiguities in this Agreement against the drafting Party has no application and
is expressly waived.

            (n) This Agreement may be executed in two or more counterparts, all
of which shall be considered as one and the same instrument and shall become
effective when one or more counterparts have been signed by each of the Parties
and delivered to the other Party.

            (o) This Agreement may be executed by facsimile signature and a
facsimile signature shall constitute an original for all purposes.

                                       16
<PAGE>

            IN WITNESS WHEREOF, the Parties hereto have executed this Agreement
as of the date first written above.

                                   CRITICARE SYSTEMS, INC.

                                   By: /s/ Emil Soika
                                       --------------------------------
                                         Name: Emil Soika
                                         Title: President and CEO

                                   BLUELINE CATALYST FUND VII, L.P.

                                   By: BlueLine Partners, L.L.C.
                                                Its: General Partner

                                   By: /s/ Scott Shuda
                                       --------------------------------
                                          Name: Scott Shuda
                                          Title: Manager

                                   BLUELINE PARTNERS, L.L.C.

                                   By: /s/ Scott Shuda
                                       --------------------------------
                                          Name: Scott Shuda
                                          Title: Manager

                                   BLUELINE CAPITAL PARTNERS, L.P.

                                   By: BlueLine Partners, L.L.C.
                                               Its: General Partner

                                   By: /s/ Scott Shuda
                                       --------------------------------
                                          Title: Manager

                                   BLUELINE PARTNERS, L.L.C.

                                   By: /s/ Scott Shuda
                                       --------------------------------
                                          Name: Scott Shuda
                                          Title: Manager

                   [Signature Page to April 2, 2007 Agreement]

                                       17
<PAGE>

                                    EXHIBIT A

News Release
________________________________________________________________________________

FOR IMMEDIATE RELEASE

Contact:      Emil Soika, President and CEO--Criticare         (262) 798-8282
              Joel Knudson, Vice President-Finance--Criticare  (262) 798-5335
              Scott Shuda, Managing Director--BlueLine         (925) 988-0285

CRITICARE AND BLUELINE REACH AGREEMENT ON BOARD COMPOSITION

MILWAUKEE--(BUSINESS WIRE)--April 2, 2007--CRITICARE SYSTEMS, INC.
(AMEX:CMD-News). Criticare Systems, Inc. today announced that it has entered
into an agreement with BlueLine Partners, L.L.C. and its affiliates, who as a
group hold approximately 11.2% of Criticare's total outstanding common stock,
ending BlueLine's efforts to reform Criticare's Board of Directors via a
solicitation of stockholder consents.

Pursuant to the agreement, the size of the Criticare Board has been increased
from six to seven members. Criticare has a classified Board of Directors whose
members serve staggered three-year terms. William Moore, a principal of
BlueLine, has been appointed to the class of directors whose terms expire at the
2009 annual meeting of Criticare stockholders, and Robert Munzenrider, who is
not affiliated with BlueLine, has been appointed to the class of directors whose
terms expire at the 2008 annual meeting. In connection with such appointments,
Stephen Tannenbaum agreed to resign from the Criticare Board, in order to help
facilitate the agreement for the benefit of the Criticare stockholders, and has
been replaced by Mr. Munzenrider as the Chairman of Criticare's Audit Committee.
In conjunction with the new appointments, BlueLine has entered into a
"standstill" with Criticare that, among other things, precludes BlueLine from
initiating new consent solicitations from the date of the agreement until the
30th day prior to Criticare's 2009 annual meeting of stockholders.

Mr. Moore (58) has been a director of BlueLine since February 2004. From March
2003 until February 2004, Mr. Moore was a general partner of Alpine Partners, a
venture capital firm. Mr. Moore served as Chief Executive Officer of
Metasensors, Inc., a medical device company, from August 1997 to March 2003. Mr.
Moore is a co-founder and director of Natus Medical Inc., a NASDAQ-quoted
medical device company.

                                       18
<PAGE>

Mr. Munzenrider (61), who currently serves on the board of directors (and the
audit and governance/nominating committees) of NYSE-listed Viad Corp. and on the
board of directors (and the audit and compensation committees) of NASDAQ-listed
ATS Medical, Inc., previously acted as senior officer of several corporations,
including as Vice President and Chief Financial Officer of St. Jude Medical,
Inc., an international medical device manufacturing and marketing company, Vice
President and Chief Financial Officer of the Glass Services Segment of Apogee
Enterprises, and Executive Vice President and Chief Financial Officer of Eliance
Corp.

"We are confident that we have reached an agreement that will allow us to move
past the events of the last six months. We look forward to a constructive
relationship with Messrs. Moore and Munzenrider as we work toward the common
goal of advancing Criticare. The Company is very grateful and appreciative to
Steve Tannenbaum, who has graciously agreed to resign his position as a Company
director and Chairman of the Audit Committee in order to help facilitate this
agreement for the benefit of the stockholders, for his years of dedicated and
faithful service to the Board and to the Company," said Emil Soika, the
Company's President and Chief Executive Officer.

"BlueLine is pleased to have arrived at an arrangement where we can work with
the management and Board of Criticare to advance the best interests of the
Company's stockholders," Mr. Moore stated. "With everyone pulling in the same
direction, we believe Criticare has the potential to create significant value."

Criticare Systems, Inc. (www.csiusa.com) designs, manufactures, and markets
cost-effective patient monitoring systems and noninvasive sensors for a wide
range of hospitals and alternate health care environments throughout the world.

This press release contains forward-looking statements. Such statements refer to
the Company's beliefs and expectations. Forward-looking statements are subject
to certain risks and uncertainties that could cause actual results to differ
materially from those described. Such uncertainties include, but are not limited
to, the timely completion of new products, regulatory approvals for new
products, the risk of new and better technologies, risks relating to
international markets, as well as general conditions and competition in the
Company's markets. Other risks are set forth in Criticare's reports and
documents filed from time to time with the Securities and Exchange Commission.

                                       19
<PAGE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]